1. Scrip
  2. >>R&D
  3. >>Clinical Trials

2seventy/BMS Halt Abecma Maintenance Trial As Landscape Evolves

 
• By Alaric DeArment

The companies said they would stop enrollment in the KarMMa-9 trial of Abecma/lenalidomide due to how the treatment paradigm has shifted since the study started.

• Source: Shutterstock

2seventy Bio, Inc. and Bristol Myers Squibb Company have hit a snag in efforts to expand the market reach of the CAR-T cell therapy Abecma (idecabtagene vicleucel) as the companies had to stop a Phase III trial of the cell therapy due to shifts in how multiple myeloma is treated.

2seventy said 25 September that it would discontinue enrollment of the KarMMa-9 trial of the BCMA-directed cell therapy as a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 
• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

2025’s Biggest Launches – Half-Year Progress Report

 
• By Andrew McConaghie

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.